Restricted approval of rituximab and adalimumab
NICE technology appraisals: Rituximab and Adalimumab
NICE issues guidance on managing urinary tract infection in children
Guideline "Urinary tract
infection in children: diagnosis, treatment and long-term management"
NICE allows MS drug for specific patients
Natalizumab (Tysabri) has been recommended
Scottish Executive keeps community services for long-term conditions
in its sights
Consultation: "Better
health, better care"
|
|
